<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36731873</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Risk factors associated with COVID-19 in systemic lupus erythematosus: Results from a longitudinal prospective cohort.</ArticleTitle><Pagination><StartPage>560</StartPage><EndPage>564</EndPage><MedlinePgn>560-564</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231155837</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a longitudinal prospective study across 15 rheumatology centres during the first wave of the pandemic to understand the risk factors contributing to COVID-19 in SLE patients. During the 6&#xa0;months follow-up, those who tested positive for COVID-19, their clinical course and outcome information were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Through the study period (April-December 2020), 36/1379 lupus patients (2.9%) developed COVID-19. On analysing the COVID-19 positive versus negative cohort during the study period, male gender (adjusted RR 3.72, 95% C.I. 1.85,7.51) and diabetes (adjusted RR 2.94, 95% C.I. 1.28, 6.79) emerged as the strongest risk factors for COVID-19, in the adjusted analysis. There was no significant influence of organ involvement, hydroxychloroquine, glucocorticoid dosage (prednisolone&lt; 7.5&#xa0;mg or &#x2265; 7.5&#xa0;mg/day) or IS on the risk of COVID-19. There was only one death (1/36) among the lupus patients due to COVID-19.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Traditional risk factors rather than lupus disease process or IS influenced the risk of COVID-19 in our cohort.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Manipal Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">74967</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shobha</LastName><ForeName>Vineeta</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5271-0766</Identifier><AffiliationInfo><Affiliation>St John's Medical College Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">29157</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shenoy</LastName><ForeName>Padmanabha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CARE Hospital, Kochi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S</LastName><ForeName>Chandrashekara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2661-9840</Identifier><AffiliationInfo><Affiliation>ChanRe Rheumatology and Immunology Centre, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sharath</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>OARC, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daware</LastName><ForeName>Manisha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Narayana Health City, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haridas</LastName><ForeName>Vikram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Arthritis Superspeciality Centre, Hubli, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janardana</LastName><ForeName>Ramya</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>St John's Medical College Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">29157</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Benzeeta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>St John's Medical College Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">29157</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodishala</LastName><ForeName>Chanakya</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>St John's Medical College Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">29157</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramaswamy</LastName><ForeName>Subramanian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>JSS Medical College, Mysore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S</LastName><ForeName>Nagaraj</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Columbia Asia, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">476829</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Vikramraj</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Bhagwan Mahaveer Jain Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">78767</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Yogesh Preet</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Manipal Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">74967</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singhai</LastName><ForeName>Shweta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sakra Hospital, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C</LastName><ForeName>Srinivasa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fortis Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">500914</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jois</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Vikram Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">257520</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Vijay K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Manipal Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">74967</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dharmapalaiah</LastName><ForeName>Chethana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Aster CMI, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">485379</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kn</LastName><ForeName>Sangeetha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anagha Hospital, Mysore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balebail</LastName><ForeName>Dharmanand</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vikram Hospital, Bangalore, India.</Affiliation><Identifier Source="RINGGOLD">257520</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">autoimmune rheumatic diseases</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>20</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36731873</ArticleId><ArticleId IdType="pmc">PMC9899665</ArticleId><ArticleId IdType="doi">10.1177/09612033231155837</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pego-Reigosa JM, Nicholson L, Pooley N, et al.The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. Rheumatol Oxf Engl 2021; 60(1): 60&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785308</ArticleId><ArticleId IdType="pubmed">33099651</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, Sawalha AH. SARS-CoV-2 and systemic lupus erythematosus. Curr Rheumatol Rep 2021; 23(2): 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842169</ArticleId><ArticleId IdType="pubmed">33511495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Alarc&#xf3;n GS, Izadi Z, et al.Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance. Ann Rheum Dis 2022; 81: 970&#x2013;978. DOI: 10.1136/annrheumdis-2021-221636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221636</ArticleId><ArticleId IdType="pmc">PMC8882632</ArticleId><ArticleId IdType="pubmed">35172961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzalla Cassione E, Zanframundo G, Biglia A, et al.COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 2020; 79(10): 1382&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pubmed">32398281</ArticleId></ArticleIdList></Reference><Reference><Citation>Shobha V, Chanakya K, Haridas V, et al.Do all patients with rheumatic diseases have a higher risk of COVID 19? initial results from the Karnataka rheumatology association COVID 19 cohort study (KRACC). Indian J Rheumatol 2021; 16(2): 164.</Citation></Reference><Reference><Citation>Patil A, Chanakya K, Shenoy P, et al.A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases. BMC Rheumatol 2022; 6(1): 32. DOI: 10.1186/s41927-022-00264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-022-00264-0</ArticleId><ArticleId IdType="pmc">PMC9192133</ArticleId><ArticleId IdType="pubmed">35698182</ArticleId></ArticleIdList></Reference><Reference><Citation>Revised strategy for COVID 19
testing in India (Version 4).  [Internet]. cited 2022 30th
November. 2022. Available from:
https://www.icmr.gov.in/pdf/covid/strategy/Strategey_for_COVID19_Test_v4_09042020.pdf</Citation></Reference><Reference><Citation>Pablos JL, Abasolo L, Alvaro-Gracia JM, et al.Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis 2020; 79(9): 1170&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299645</ArticleId><ArticleId IdType="pubmed">32532753</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoglio IM, Valim JMdeL, Daffre D, et al.Poor prognosis of COVID-19 acute respiratory distress syndrome in lupus erythematosus: nationwide cross-sectional population study of 252 119 patients. ACR Open Rheumatol 2021; 3(11): 804&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8593786</ArticleId><ArticleId IdType="pubmed">34423922</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiker R, Pakhchanian H, DeYoung C, et al.Short term outcomes of COVID-19 in lupus: propensity score matched analysis from a nationwide multi-centric research network. J Autoimmun 2021; 125: 102730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8501265</ArticleId><ArticleId IdType="pubmed">34649723</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashedi J, Mahdavi Poor B, Asgharzadeh V, et al.Risk factors for COVID 19. Infez Med 2020; 28(4): 469&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257620</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi D, Tani C, Elefante E, et al.Impact of first wave of SARS-CoV-2 infection in patients with systemic lupus erythematosus: weighting the risk of infection and flare. PLoS One 2021; 16(1): e0245274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7806138</ArticleId><ArticleId IdType="pubmed">33439910</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, et al.Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2020; 79(7): 859&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillaume D, Magalie B, Sina E, et al.Antirheumatic drug intake influence on occurrence of COVID-19 infection in ambulatory patients with immune-mediated inflammatory diseases: a cohort study. Rheumatol Ther 2021; 8(4): 1887&#x2013;1895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444183</ArticleId><ArticleId IdType="pubmed">34529226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendebien Z, Frenckell C, Ribbens C, et al.Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments. Ann Rheum Dis 2021; 80(6): e94&#x2013;e94.</Citation><ArticleIdList><ArticleId IdType="pubmed">32586921</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res 2021; 232: 13&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749645</ArticleId><ArticleId IdType="pubmed">33352298</ArticleId></ArticleIdList></Reference><Reference><Citation>Pileggi GS, Ferreira GA, Reis APMG, et al.Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. Adv Rheumatol 2021; 61(1): 60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496137</ArticleId><ArticleId IdType="pubmed">34620246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentsch CT, DeVito NJ, MacKenna B, et al.Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol 2021; 3(1): e19&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745258</ArticleId><ArticleId IdType="pubmed">33349815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>